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ABSTRACT 
 
Suicide is an important cause of death worldwide. HIV+ patients and heroin users are groups with elevated 
risk of suicide when separately compared to general population. Suicide has been also associated with 
psychiatric disorders as well as high cortisol levels. Still, suicide is hardly ever predicted and biological 
correlates to suicide are lacking. We aimed to investigate the effect of HIV infection on suicidal risk among 
heroin users in treatment with methadone, through a comparative study. Additionally, we assessed factors 
known to influence suicidal risk like stress (based on both cortisol levels and self-reported stress), anxiety 
and depression among HIV+ heroin users. A cross-sectional study was performed. Thirty-seven (37) HIV+ 
and fifty-two (52) HIV- heroin users participated in our study. Psychological evaluation was performed using 
the scales for depression (Hospital Depression Scale - HDS), anxiety (Hospital Anxiety Scale - HAS), 
perceived stress scale (PSS-10) and Beck Scale of Suicidal Ideation (BSS). Simultaneously, we measured 
salivary cortisol due to its correlation with stress. Our results revealed that the HIV+ heroin users had higher 
total suicidal ideation scores compared to HIV- heroin users. No statistically significant differences across 
groups were detected in neither perceived stress scores, nor in anxiety and depression frequencies. Among 
HIV+ patients, the higher the total self-reported scores reported by participants, the higher the total suicidal 
ideation scores obtained. Likewise, salivary cortisol levels correlated positively with total suicidal ideation 
scores. Individuals classified as presenting depression, as well as those classified as presenting anxiety 
showed higher total suicidal ideation scores when compared to those who were classified as presenting 
“no” depression or presenting “no” anxiety, respectively. These results suggest an additional effect of HIV 
infection on the risk of suicide among heroin users. Parallel to this, our findings highlighted the relevance 
of screening psychiatric disorders among heroin users in order to prevent suicide. Since a correlation 
between the cortisol level and suicidal ideation scores was detected, and cortisol level was shown to be a 
good predictor of suicidal ideation in a regression model of suicide made, it might be further explored as 
predictor of suicide risk. 
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RESUMO 
 
O suicídio é uma causa importante de morte a nível mundial. Pacientes VIH+ e usuários de heroína são 
grupos com elevado risco de suicídio quando isoladamente comparados com a população geral. O suicídio 
tem sido igualmente associado a perturbações psiquiátricas bem como a níveis elevados de cortisol. 
Entretanto, é difícil prever o suicídio e marcadores biológicos que se associem ao suicídio estão em falta. 
O presente estudo teve como objetivo investigar o efeito da infeção pelo VIH no risco de suicídio entre 
usuários de heroína em tratamento com metadona, através de um estudo comparativo. Adicionalmente 
avaliaram-se fatores conhecidos como tendo influência na ideação suicida como o stresse (baseados nos 
níveis de cortisol e no stresse percebido), ansiedade e depressão em usuários de heroína VIH+. Foi feito 
um estudo transversal. Trinta e sete (37) usuários de heroína VIH+ e cinquenta e dois (52) usuários de 
heroína VIH- participaram no nosso estudo. A avaliação psicológica foi feita através de escalas de 
depressão (Escala Hospitalar de Depressão), ansiedade (Escala Hospitalar de Ansiedade), Escala de 
Stresse Percebido (PSS-10) e Escala de Ideação Suicida de Beck (BSS). Em simultâneo, mediram-se os 
níveis de cortisol dos participantes devido à sua correlação com o estresse. Os resultados revelaram que 
os usuários de heroína VIH+ tiveram pontuações totais mais altas de ideação suicida do que os usuários de 
heroína VIH-. Não foram encontradas diferenças estatisticamente significativas entre os dois grupos nas 
pontuações de stresse percebido nem na frequência de ansiedade e depressão. Entre os pacientes 
usuários de heroína VIH+, quanto mais altas as pontuações de stresse percebido mais altos os valores 
totais de ideação suicida obtidos. Da mesma forma, os níveis de cortisol salivar tiveram uma correlação 
positiva com as pontuações totais de ideação suicida. Por outro lado, os participantes classificados como 
tendo depressão ou tendo ansiedade tiveram valores mais altos de ideação suicida do que os que foram 
classificados como não tendo depressão ou não tendo ansiedade, respetivamente. Estes resultados 
sugerem um efeito adicional da infeção pelo VIH no risco de suicídio entre pacientes usuários de heroína. 
Paralelamente, os nossos resultados salientam a importância do rastreio de patologias psiquiátricas entre 
usuários de heroína tendo em vista a prevenção do suicídio. Uma vez que o nível de cortisol correlacionou-
se com a pontuação de ideação suicida e que no modelo de regressão linear feito o nível de cortisol 
revelou-se um bom preditor de ideação suicida, poderá ser mais explorado como preditor de risco 
suicidário.  
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1.1. General background 
Human Immunodeficiency Virus (HIV) is a lentivirus that causes a progressive immunodeficiency leading to 
AIDS (Acquired Immunodeficiency Syndrome) (Doitsh et al., 2014). Although the first cases of the 
syndrome were reported in men having sex with men (MSM) near 1981, it was in 1983 that the virus was 
firstly identified (UNAIDS & WHO, 2003). Since then, the global prevalence increased from about 8 million 
people infected with HIV in 1990 (WHO, UNAIDS, & Unicef, 2011) to approximately 33.2 million people, 
with an incidence estimated of 2.7 million people in 2007 (Getahun, Gunneberg, Granich, & Nunn, 2010). 
By the end of 2012, the estimated prevalence of HIV infection worldwide was of 35.3 million people, with 
an incidence of 2.3 million and  nearly 1.6 million people had died of AIDS (UNAIDS, 2013). Evidences 
suggest a decrease in HIV epidemics all around the world, except in specific groups such as injecting drug 
users in both Central Asia and Eastern Europe and young women in Sub-Saharan Africa (Beyrer, Baral, & 
Griensven, 2013). As for men having sex with men, infections in HIV are still increasing all through most 
countries (Wallace, Li, & McDaid, 2014) (Beyrer et al., 2013).  
HIV/AIDS prevalence in Portugal in 2012 was of 42 580 people, with an incidence of 776 people 
(Departamento De Doencas, Infecciosas, & Sida, 2013) which represents a concern compared to other 
European countries, highlighting the need to intensify counseling and testing (Yazdanpanah et al., 2013). 
The transmission of HIV occurs through sexual and perinatal routes, blood transfusion or use of infected 
needles (Hessol, Gandhi, & Introduction, 2005). The risk behaviors mostly associated with the disease are 
non-protected sexual anal intercourse (Beyrer et al., 2013), multiple sexual partners (Vuylsteke et al., 
2012), and injecting drug use (Choopanya et al., 2013) . 
The HIV binds to its receptor on the surface of cells from the immune system. The most important being 
the CD4, on the surface of CD4+ T lymphocytes. The HIV binds to the host cells making use of one of its 
glycoproteins – the gp120 (Adamson & Freed, 2011). Upon this interaction, the virus membrane fuses 
with the cell membrane and the replication cycle within the cell is initiated (Citron, Brouilette, & Beckett, 
2005) If the patient does not receive appropriate anti-retroviral treatment, the viral replication progresses 
followed by destruction of the CD4+ T lymphocytes, with advent of more severe diseases until death (Vlahov 
et al., 1998). CD4+ T lymphocytes counts and blood viral load measures are extremely useful to determine 
the progression of the disease (Li et al., 1998) . 
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Immediately after the discovery of the disease, there was no treatment available (CDC, 2011). The first 
drug approved as Anti-Retroviral Therapy (ART) was zidovudine (AZT) in 1987, still with high mortality rates 
(UNAIDS, 2013). Only in 1996 the advantages of giving triple combined drugs were highlighted with 
significant decrease in mortality and morbidity (CDC, 2011), being ART nowadays usually referred to as 
Highly Active Anti-Retroviral Therapy (HAART) (Vercauteren et al., 2013). 
 
1.2. HIV and central nervous system 
Besides the effects on the immune system, it is well-established that HIV infects the Central Nervous 
system (CNS) at early stages and replicates in the brain parenchyma targeting the microglial cells (Ellis, 
Calero, & Stockin, 2009). It has been suggested that HIV reenters the brain parenchyma during periods of 
high viral load, causing neuronal deterioration and death (Kaul, Zheng, Okamoto, Gendelman, & Lipton, 
2005). This neuronal dysfunction and death occur most probably through indirect mechanisms involving 
inflammatory cytokines from the host cells than direct HIV neuronal damage (Kaul, Garden, & Lipton, 
2001)Nevertheless, the symptoms of neurologic deterioration do not seem to appear during the early 
stages being more frequently associated with late stages of the disease (Ellis et al., 2009). In the final 
stages of the disease, the neurologic symptoms may be associated with the infection of the central nervous 
system by the HIV and/or due to opportunistic infections and/or secondary malignancies (Kranick & Nath, 
2012). Neurocognitive and neurological syndromes associated with AIDS include peripheral neuropathy, 
Progressive Multifocal Leukoencephalopathy (PML), meningoencephalitis, cerebral toxoplasmosis and so 
forth (Citron et al., 2005).  
Considerable interest has been given to cognitive alterations associated with HIV, being a syndrome usually 
found due to AIDS in the absence of opportunistic diseases (Yeh et al., 2000) the so called HIV Associated 
Dementia complex (HAD, which affects cognitive function, leads to motor impairment and behavioral 
alterations (Kaul et al., 2005) a subject of much research investigation (Valcour, Sithinamsuwan, Letendre, 
& Ances, 2011)  
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1.3. HIV and psychiatric disorders 
In addition to the physical and neurological abnormalities due to the disease, increasing research has 
described some emotional and behavioral phenomena occurring more frequently in the group of people 
infected with HIV (Carrico et al., 2007). Since its discovery, due to the incurability and the general 
awareness of the disease as a terminal illness, there is a perception of risk associated with the disease that 
may lead to a variety of negative feelings of fear, fatalism and impotence (Keiser et al., 2010). Together 
with this, the sexual context of the disease, since it was primarily described as a disease found in man 
having sex with men (MSM) (Beyrer et al., 2013) and sexual promiscuity brought up social discrimination 
as well as perception of stigma and feelings of guilt and shame to the individuals infected (Hemmati Sabet, 
Khalatbari, Abbas Ghorbani, Haghighi, & Ahmadpanah, 2013). Some models describe that these factors 
that might be present from the diagnosis and throughout the evolution of the infection might act as 
important ongoing psychosocial stressors (Carrico et al., 2007) - that can be defined as outward factors 
that endanger one´s welfare (Pearlin, Menaghan, & Lieberman, 2009). Additionally, these psychiatric 
stressors may lead to psychiatric disorders like depression, anxiety and suicidal ideations (Carrico et al., 
2007). However, since then people have been reacting differently to a HIV infection diagnosis Social 
support (Yi et al., 2006) religiosity (Yi et al., 2006), individuals appraisal of the event are some factors that 
play an important role in reducing the negative impact of the psychosocial stress associated to the disease 
(Tuck, McCain, & Elsiwick, 2008) and strategies that emphasize the involvement of family and friends as 
well as cognitive behavioral therapy have been benefiting the quality of life of people infected with HIV 
(Hemmati Sabet et al., 2013).  
Interestingly, despite the knowledge of the HIV infection and disease evolution mechanisms, better 
treatments (HAART) developed and the resulting increased life expectancy, the perceived stress and 
psychological distress conditions (like experiencing anxiety and depression symptoms) (Drapeau, Marchand, 
& Beaulieu-prévost, 2007) are still more prevalent in HIV positive patients compared to negative controls 
(Morrison et al., 2002). Indeed, in the era of HAART, anxiety, depression and stress have shown to impair 
some important aspects of the treatment and transmission, such as the adherence and sexual risk 
behavior that have been shown to improve with the management of the disorders (Hemmati Sabet et al., 
2013). 
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1.4. HIV, suicide and injecting drug users 
Suicide that is the act of willfully killing oneself (OECD, 2013), is a public health burden in many countries 
all around the world (OMS, 2000) (Jin et al., 2014) (OECD, 2013). It is a complex and often multifactorial 
phenomenon, which is explained usually combining several variables (Minayo, Cavalcante, & Souza, 2006). 
2011). Events of life (Currier & Mann, 2009)(Pereira, 2011), personality traits (Maloney, Degenhardt, 
Darke, & Elliot, 2010) as well as genetic predisposition (Pereira, 2011) may also be associated to its 
occurrence. The WHO (OMS, 2000)described the frequency of  suicide as being higher in young men, 
people with alcoholism, drug users and people with chronic diseases with poor prognosis.  
Some authors found that the risk of suicide is higher in the group of risk of HIV infection both in infected 
and not infected people. That is, people at risk of committing suicide share some characteristics of people 
at risk of getting infected with HIV, hence it is unclear whether this event is a result of disease or is part of 
the vulnerability of the group (Starace, 1993)(Kelly et al., 1998). As for injecting drug use, it is a practice 
commonly intersected with HIV infection and may independently constitute a risk factor for suicide (Jin et 
al., 2014).  
Patients infected with HIV have higher suicide rates than general population (Bragança & Palha, 2011). 
The suicidal ideations are commonly found anytime throughout the disease (Carrico et al., 2007) though 
some studies suggest that they are more prominent during disclosure, when the first symptoms and 
signals of the disease appear or in association with morphological alterations and other side effects of 
medication (Citron et al., 2005). Another interesting aspect is that factors that may independently lead to 
suicide are more pronounced in HIV+ people: psychiatric comorbidities are increased among HIV+   
individuals, as aforementioned, highlighting the importance of treating these disorders in order to reduce 
suicidal risk. This evidence is demonstrated by Keiser et al, 2010 wherein among HIV+ individuals who died 
by suicide about 23% were not receiving any psychiatric treatment. Similarly, psychiatry disorders are 
frequently found in the history of injecting drug users who attempt and commit suicide (Kuramoto, 
Chilcoat, & Ko, 2012). 
Regarding biological aspects, prolonged heroin use has been associated with a cognitive impairment and 
altered behavior through alterations in the opioid system (Ersche & Sahakian, 2013). Meanwhile, some 
literature postulates that the metabolism of tryptophan, the precursor of serotonin that is a 
neurotransmitter associated to mood disorders might be altered due to HIV infection (Widner, Laich, 
Sperner-Unterweger, Ledochowski, & Fuchs, 2002). This is supported by Zangerle et al, wherein not only 
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HIV infection was suggested to increase the degradation of tryptophan, but also this effect was partially 
reversed by HAART. Since there is a strong correlation with neuropsychiatry abnormalities through immune 
activation, the metabolism of tryptophan gave insight of possible mechanisms through which the immune 
system and the Central Nervous System may interact (Widner et al., 2002). 
 
1.5. Neurobiology of stress, depression and anxiety in relation with immunity 
There are evidences of a bidirectional interaction between the immune system and the central nervous 
system (Dantzer, 2004). The mechanism by which this interaction occurs is more often appointed to the 
Hypothalamic-Pituitary-Adrenal (HPA) axis, in that, an excess of circulating glucocorticoids – the final 
product of the activation of the HPA system – is responsible by an altered immune response (Sternberg, 
2007). In situations of chronic stress, the excess of glucocorticoids resulting from HPA activation, leads to 
a reduced response of glucocorticoids receptors through negative feedback, which might result in 
stimulated release of pro inflammatory cytokines (which is inhibited by genes activated by glucocorticoids 
receptors in normal functioning) (Raison, Capuron, & Miller, 2006). In the brain, the pro-inflammatory 
cytokines have been suggested to interfere with the metabolism of neurotransmitters such as serotonin 
(5HT), dopamine (DA) norepinephrine (NE) in different neuro circuitries involved in mood, anxiety, and 
motor activity namely amygdala, basal ganglia, prefrontal cortex that may explain the psychiatric disorders 
(Miller, Maletic, & Raison, 2009) (Raison, Capuron, & Miller, 2012), as illustrated in Figure 1. 
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Figure 1. Psychosocial stress inducing immune response activation (from Raison et al, 2006). 
 
The evidence of the interaction between the central nervous system and the immune system was primarily 
given by changes in the behavior during acute infectious diseases, like social avoidance, anhedonia, fatigue, 
alterations in sleep and appetite patterns and so forth, referred to as sickness behavior (Dantzer, 2004). 
These behavior alterations were initially considered to be important by reducing the spread of the disease 
as well as to save energy resources to other metabolic processes from the disease (Dantzer, 2004) (Miller 
et al., 2009). Further, depression has been associated with increased pro-inflammatory profile (Raison et 
al., 2012) in that some studies showed an improve in depressive symptoms in patients treated with Tumor 
Necrosis Factor (TNF) antagonist (Raison et al., 2012) as well as modulation of behavior by manipulating 
cytokines in experimental animal models (Mesquita et al., 2008). 
As for psychological distress conditions like anxiety symptoms and depressive symptoms, the measures of 
cellular immunity might be found altered although with controversial findings, some showed association 
between depression and anxiety with low CD4+ T lymphocyte counts and progression to AIDS (Leserman, 
2008) and others found no association (Kinyanda, Hoskins, Nakku, Nawaz, & Patel, 2011). Whilst, some 
studies further indicate other measures of cellular immunity that could better clarify the association 
wherein, a lower Natural Killer (NK) activity and higher activated CD8+ T lymphocyte counts and HIV viral 
load are appointed to be associated with major depression and anxiety symptoms (Evans et al., 2002). As 
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potential mechanisms underneath, models of interaction between elements of innate immunity such as NK 
and cytotoxic T cell activation mediating higher levels of psychological distress and impaired HIV disease 
severity are used to explain association (Greeson et al., 2008), as represented in Figure 2. 
 
 
Figure 2. Hypothesized model of interaction between psychological distress and HIV disease mediated by 
elements of natural immunity (from Greeson et al, 2008). 
 
1.6. Cortisol and suicide 
Increasing evidence of association between cortisol and suicide has been suggested (Brunner et al., 
2002) ;(Jokinen et al., 2007); (Sequeira et al., 2012) and abnormalities in the serotonergic system often 
correlate with suicide attempts (Mann, Brent, & Arango, 2001). In a study by Chatzittofis et al, 2013 on 
suicide attempters, a correlation between suicide and high cortisol concentrations was found. Again the 
dysregulation of the HPA-axis together with dysfunction of the central serotonin system, as shown by 
Ghaziuddin et al, 2014, seems to be implicated in suicidal ideation and complete suicide. These findings 
are in line with evidence of an association between high cortisol levels and depression and anxiety 
(Sequeira et al., 2012), that are well-established risk factors for suicide, though studies showing cortisol 
levels independently predicting suicide are lacking (Dwivedi, 2012). 
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The strategies being used to date in some countries, such as counseling and group meetings created for 
people to share their “living with HIV” experiences have been shown to be important in the quality of life of 
the individuals, yet they might not be enough in preventing suicide that requires skills from professionals 
and depends very much on one’s temper to be willing to talk about his or her fears and intents. Moreover, 
people appraise and react differently even facing similar situations. By understanding the factors 
underneath this variation, one could get closer to those who need more attention. If it is shown that there is 
a biological and available resource associated to it, it would be valuable to the services to benefit of it as 
additional tool to at least more quickly identify individuals that would more likely attempt suicide.  
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2. AIMS 
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The study aims to: 
1) Examine suicidal ideation in HIV+ patients that are heroin users in comparison with HIV- heroin users. 
2) Investigate associations between suicidal ideation and the following parameters: stress levels (based on 
both perceived stress scale - PSS-10 - scores and cortisol levels), anxiety and depression (Hospital Scale for 
Depression and Anxiety- HADS) among HIV+ patients who are concomitantly heroin users. 
3) Access intrinsic factors associated with the occurrence of suicide in HIV+ heroin users, namely history of 
psychiatric diagnosis, familiar history of suicide, past suicide attempts, time since HIV disclosure, and so 
forth. 
 
Results will provide additional tools to draw interventional plans more focused on risk factors, increasing 
the efficiency in screening suicidal risk within this group. 
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3. METHODOLOGY 
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3.1. Study area and sample size determination 
The cross-sectional study was carried out in DICAD (“Departamento de Intervenção nos Comportamentos 
Aditivos e nas Dependências”) in Braga. 
The sample included in this study is composed of heroin users with a positive diagnosis of HIV infection 
who are in the program of substitution of drugs by methadone in an outpatient regime. Enrolment took 
place from November 2013 to April 2014. 
 
Excluding criteria 
- Patients younger than 18 years and older than 55. 
- Severe psychiatric disorders and/or cognitive impairment (clinically accessed). 
- Severe diseases of the Central Nervous System (clinically accessed). 
- Pregnant women. 
- Patients treated with corticosteroids in the previous semester. 
- Patients taking oral anti-conceptive. 
- Patients with oral infections. 
- Patients not able to provide informed consent. 
A control group of patients that are also heroin users in treatment with methadone, with a negative result of 
HIV infection in the previous two years and without declared risk behavior was enrolled at the same time.  
 
Procedure 
Patients were approached after taking methadone and asked to participate. For those who accepted to be 
enrolled in the study after an explanation of the procedure and purposes of the study, a small interview was 
driven in order to fill the form for socio-demographic data as well as the scales and saliva sample was 
collected. 
We asked for C.R.I (“Centro de Respostas Integradas”) ethic committee permission and obtained informed 
consent of each volunteer. 
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3.2. Data collection 
 
3.2.1. SOCIO-DEMOGRAPHIC DATA AND NEUROPSYCHOLOGICAL ACCESS  
A questionnaire about socio-demographic information was used to access individual’s personal data and 
lifestyle, namely:  age, gender, marital status, residence, occupation, years of education, smoking habits, 
alcohol consumption, use of drugs and intake of oral anti-conceptive. 
This form also enquired about clinical data: intake of medication to treat psychiatric disorders, psychiatric 
medical history, previous suicide attempts, comorbidities, sexual orientation, and length of time from 
disclosure, details concerning HAART. 
 
The HADS (Hospital Anxiety and Depression Scale) was used to screen for depression and anxiety (Snaith, 
2003). HADS is a form composed of 14 questions - 7 for depression and 7 for anxiety - each one rated 
from 0 to 3 with a final total cut point scoring of 8 meaning the presence of the disorder in both subscales 
(Álvaro et al., 2007). 
 
A Portuguese version of the PSS-10 (Perceived Stress Scale) - a psychological measure of the extent to 
which events in one’s life are recognized as excessive demands to be tolerated(Cohen, Kamarck, & 
Mermelstein, 1983) – was applied. It is composed by 10 queries about perception of uncontrollability and 
unpredictability concerning to different aspects of life during the previous month. Answers are given in form 
of frequency varying from never (0) to very often (4), with a minimum total score of 0 and a maximum of 
40. Scores are calculated by summing reversing responses depending on the positivity meaning of the 
item. As general interpretation, those who scored more are appraising life more stressfully. 
 
The BSS (Beck Scale for Suicidal Ideation) was provided to participants to evaluate suicidal risk 
assessment. The BSI is a scale with 19 items with answers organized from less to more serious condition 
in each item concerning attitudes and wishes about suicide, simultaneously looking for one individual’s 
ability to consummate the intent when detected as well as for opportunities. There are no cut points for the 
final scores - higher scores obtained are interpreted like more severity of ideation and the participant is 
more likely to attempt suicide - (Cochrane-Brink, Lofchy, & Sakinofsky, 2000).  
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3.2.2. ACCESS OF CORTISOL CONCENTRATION IN THE SALIVA 
Samples of saliva were used to access salivary cortisol levels (Hellhammer, Wüst, & Kudielka, 2009). The 
concentration of cortisol in the saliva is about 1/3 inferior to that in the blood. Nevertheless, the evaluation 
of cortisol in the saliva is useful since its level is strongly correlated with that in the blood when evaluated in 
response to stress and saliva is much easier to collect (Petrowski, Wintermann, Schaarschmidt, Bornstein, 
& Kirschbaum, 2013). 
Small tubes with a piece of cotton inside (salivettes) for salivary collection were used. They were distributed 
after an explanation of its use, between 9 and 12 a.m., regarding the recommendations about the time 
between meals and collection procedures: patients were advised not to smoke or eat 30 min before 
collection. They should open the tube until access the cotton, put it in mouth keeping 1-2 min under the 
tongue or chewing it. Then return it back to the tube, avoiding manual contact. The procedure was done 
under supervision. After collection, salivettes were stored at -20˚C.  
In average after 1 week, the small tubes were centrifuged at 2000g during 2 min, distributed in aliquots 
with the minimum required of 0.5 ml and stored at -80 ˚C until analysis.  
Salivary cortisol levels were determined by competitive ELISA (enzyme-Linked Immunoassay) , following the 
instructions indicated by the manufacturer, with  an analytical sensitivity of 0.007 µg/dl and a coefficient of 
variation intra-assay and inter-assay of 4.6% and 6%, respectively. 
The protocol to perform the competitive ELISA to quantify the cortisol is briefly described in Annex 1. 
 
Materials provided by supplier 
- Microtiter plate; 
- Enzyme conjugate; 
- Standard (6 dilution of cortisol); 
- Controls (2 solutions with known cortisol concentrations); 
- Substrate solution (TMB); 
- Stop solution (TMB); 
- Wash buffer concentrate; 
- Non-specific binding wells. 
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Materials used not provided by supplier 
- Micropippettes; 
- Plate rotator; 
- Vortex mixer; 
- Multichannel micropipette; 
- Microtiter plate reader with capacity to read absorbance at 450nm; 
- Deionised water; 
- Paper towels; 
- Pipette tips; 
- Reagent reservoirs; 
- Serological pipette (to deliver up to 24 ml); 
- Timer. 
 
The following steps were performed according to Cortisol ELISA manufacture instructions. 
- 1X wash buffer was prepared by diluting wash buffer concentrate 10-fold with deionized water (50 
ml of 10X wash buffer concentrate to 450 ml of deionized water). 
- 1:1600 dilution of cortisol enzyme conjugate was made by adding 15 µl of the enzyme conjugate 
to 24 ml of assay diluent. 
- 25 µl of each standard (containing 3, 1, 0.333, 0.111, 0.037 and 0.012 µg/dl), Control (control 
high and low), and doubled sample were pipetted into respective wells of the microtiter paper.  
- 200 µl of the diluted enzyme conjugate was pipetted into each well. The plate was shacked 
carefully after covered and incubated at room temperature on an orbital shaker during 60 minutes. 
It was washed with the diluted wash buffer and added 200 µl of substrate solution into well and 
incubated during 30 minutes at room temperature, on an orbital shaker, covered.  
- The reaction was stopped by adding 50 µl of stop solution into well.  
- Results of cortisol levels were obtained using the optic density of standard curve, using an 
automated method (Bio Rad; model 680 microplate reader). The interpretation was done using 
software of microplate manager 5.2.1. 
Results were processed using ELISA based on competition (Inder, Dimeski, & Russell, 2012). 
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3.3. Statistical analysis 
To analyze data, Statistical Package for Social Sciences (SPSS) version 22 was used. The alpha level of 
statistical significance was set at 0.05. Student´s t test for independent samples, Levene’s and Chi-square 
test were performed to compare medians between HIV+ and HIV- groups, variances and frequencies, 
respectively. To see whether the effect of belonging to one group or other on suicidal ideations could 
change whenever some variables of interest were kept constant, a sequential model of regression including 
socio-demographic and psychological variables of interest was drawn. Among HIV+ patients, student´s t test 
for independent samples was performed to compare medians between groups presenting depression and 
“no” depression, and between those presenting anxiety and “no” anxiety. Pearson correlation coefficient 
was computed to examine the correlation between both perceived stress and cortisol levels with suicidal 
ideations, separately. A model of linear multiple regression including variables found to be associated with 
suicide ideations in HIV+  patients was performed to access how accurately each variable could predict 
suicidality. 
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4. RESULTS 
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4.1. Characterization of the study population 
The characterization of the study population is summarized in Table 1. Although 89 heroin drug users 
accepted to participate in the study, 3 dropped out, 6 did not meet the inclusion criteria and 7 did not 
complete the study protocol. Thus, the study population was composed by 80 individuals: 37 HIV+ and 43 
HIV- negative, wherein 73 completed the study protocol. The mean age between the two groups was 
statistically different (HIV+ and HIV- groups mean age was 42 ± 4 and 39±7 respectively; [t (78) = 2.33; p = 
0.02; Cohen´s “d” = 0.53]. Both groups were comparable in gender [χ2 (1) = 0.36; p = 0.56; phi = - 
0.07], being the sample mostly composed by men. There was no difference on the number of years of 
education between the HIV+ patients (7.6 ± 2.7) and HIV – patients (8.1 ± 3.3); [t (77) = 0.54; p = 0.54; 
Cohen´s d = 0.17]. Both HIV+ and HIV- patients were predominantly unemployed, with no statically 
significant differences in occupation between the two groups, though the group of HIV+ had a trend to have 
higher frequency of unemployed individuals [χ2 (3) = 6.74; p=0.08; Cramer´s “V”  = 0.29]. The group of 
HIV+ patients was composed predominantly by injecting drug users, whereas the group of HIV - used other 
ways of administration rather than injection, with a statistically significant difference between both [χ2 (1) = 
0.807; p = 0.01; Cramer’s “V” = - 0.30]. Hepatitis C was the most frequent comorbidity in both groups, 
being more frequently found in the group of HIV+ patients, with a statistically significant variation in its 
frequency between the groups [χ2 (4) = 10.741;  p = 0.03; Cramer’s “V” = - 0.10]. The HIV+ group showed 
a statistically significant difference in the body mass index mean (21.0 ± 2.1) compared to HIV- (22.7 ± 
3.4); [t (70.4) = -2.69 p = 0.01, Cohen’s “d” = -0.60]. No statistically significant differences in sexual 
identity were detected across groups [χ2 (1) = 1.154; p = 0.28; Cramer’s “V” = 0.12]. 
Regarding HIV+ group, the study population was composed predominantly by men (81.1%) and single 
individuals (70.3%). 97.2% of the patients described themselves as heterosexual. Nearly 1/2 of participants 
reported to have children (43.2%) and 81.1% were currently living with either a partner or a relative. As for 
routes of transmission of the HIV, 22.2% did not know how they got infected, 19.4% reported to have been 
infected through unprotected sexual intercourse and 58.3% by sharing needles. The disclosure of the HIV 
infection was made for an average time of 11.2 years prior to interview and all participants were taking 
HAART for a mean time of 7.4 years, as shown in Table 2. 
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4.2. Comparison of the frequencies of psychiatric disorders between HIV+ and HIV- patients  
In respect to frequencies of psychiatric disorders in our study population, although the HIV+ patients 
showed a trend to have higher self-reported scores of PSS-10 (20.1± 7.1) compared to HIV- (18.7 ± 7.2), 
no statistically significant differences were found between the two groups [t (71) = 0.85, P = 0.40 d = 
0.21]. Regarding depressive symptoms based on HDS scores, the frequency were higher in the group of 
patients infected with HIV compared to HIV-, 37.8% and 22.2% respectively, but no statistically significant 
difference was found [χ2 (1) = 2.1; p = 0.20; phi = -0.17 ]. Similarly, the frequency of symptoms of anxiety 
based on HAS scores (45.9% in HIV+ patients and 41.6% in HIV- patients were not statistically significant 
different across groups [χ2 (1) = 0.14.; P = 0.81 Cohen´s “d” = -0.04], as represented in Table 1. 
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Table 1. Characterization of the study population. 
Characteristic HIV + HIV - p-value Cohen´s “d”/ phi 
Age M (SD) 
 
42 (4) 
 
39 ( 7) 
 
0.02* 
 
0.53 
 
Male/Female N 
 
30/7 
 
37/6 
 
n.s. 
 
 
-0.07 
 
Years of education  M ( 
SD) 
 
 
7.6 (±2.7) 
 
 
8.1 (±3.3) 
 
n.s. 
 
 
0.17 
 
Unemployed N (%) 
 
32 (86.4%) 
 
28 (66.7%) 
 
n.s. 
 
0.29 
 
Smoker N (%) 
 
36 (97.2%) 
 
39 (92.8%) 
 
 
n.s. 
 
0.37 
 
Alcohol ingestion N (%) 
 
15 (40.5%) 
 
14 (33.3%) 
 
n.s. 
 
-0.07 
 
Injecting drug user N (%) 
 
36 (97.2%) 
 
32 (76.1%) 
 
0.007* 
 
-0.3 
 
Psychiatric disease N (%) 
 
 
11 (42.3%) 
 
12 (28.5%) 
 
n.s. 
 
-0.30 
 
Previous suicide attempt 
N (%) 
 
 
15 (40.5%) 13 (30.9%) 
 
n.s. 
 
-0.01 
 
Hepatitis C antibody 
positive N (%) 
 
 
16 (43.2%) 
 
10 (24.3%) 
 
0.03* 
 
-0.10 
 
Body Mass Index M (SD) 
 
21.0 (±2.1) 
 
22.7 (±3.4) 
 
0.009* 
 
0.60 
 
Perceived stress score M 
(SD) 
20.1 (±7.1) 18.7 (±6.2) 
 
n.s. 
 
 
0.21 
 
Anxious N (%) 
 
17 (45.9%) 
 
5 (41.6%) 
 
n.s -0.04 
 
Depressive N (%) 14 (37.8%) 
 
8 (22.2%) 
 
n.s. 
 
-0.17 
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4.3. Comparison of suicidal ideation (BSS scores) between HIV+ patients and control 
In order to investigate whether there was a difference in suicidal ideation between HIV+ and HIV- heroin 
users, student´s t test for independent samples was performed. The total suicidal ideation scores based on 
BSS were significantly higher in the group of HIV+ patients (8.5 ± 9.0) compared to HIV- (2.7 ± 5.9) [t (71) 
= 3; p=0.002; Cohen´s “d” = 0.76], as shown in Figure 3. 
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Figure 3. BSS scores between groups of HIV+ and HIV- patients. 
 
4.4. Sequential linear multiple regression model of suicidal ideation scores and variables commonly 
associated with suicide in HIV+ and HIV- heroin users 
Since the total suicidal ideation scores were statistically different between HIV+ and HIV- patients, a 
sequential linear multiple regression was made to access whether of belonging to one group or other could 
have a statistically meaningful influence on suicidal ideations if some variables usually associated to 
suicide in literature were maintained constant. Firstly, results showed that belonging to one group or other 
was statistically significant (β = - 0.36; P = 0.002), as shown in Table 2. 
  
Table 2. Linear regression model of the HIV+ and HIV- groups and suicidal ideation scores. 
 B      (C.I.: 95%) Beta t p 
Study group -5.82 (-9.38; -
2.25) 
-0.36 -3.25 0.00 
Model: R = 0.36; R2 = 0.13; R2 adjusted = 0.12; p <0.05.  
p = 0.002**  
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Since differences in age, gender and occupational state have been shown to influence the suicidal ideation 
in general population, these variables were added to the model in order to analyze if belonging to one 
group or other would still be statistically significant. Results revealed that even if the age, gender and 
occupational state (being employed or unemployed) were kept constant, being HIV+ or HIV- would still be 
statistically significant to the gravidity of suicidal ideations  (β = - 0. 32; p = 0.009), as represented in 
Table 3. 
 
Table 3. Multiple linear regression model of socio-demographic variables and suicidal ideation scores in 
HIV+ and HIV- patients. 
 B (C.I.: 95%) Beta t p 
Study group 
-5.24 (-9.11; -
1.37) 
-0.32 -2.70 0.01 
Age 
0.01 (-0.29; 
0.31) 
0.01 0.07 0.94 
Gender 
0.32 (-4.41; 
5.05) 
0.01 0.14 0.89 
Occupational status 
2.40 (-1.98; 
6.78) 
0.13 1.09 0.28 
Model: R = 0.38; R2 = 0. 14; R2adjusted: 0.09; p <0.05. 
 
Besides, since stress, depression and anxiety are well-established correlates of suicide, the psychological 
measures of perceived stress, depression and anxiety were also added to the model to examine if the 
scores of perceived stress and frequencies of anxiety and depression were maintained constant, the fact of 
belong to the HIV+ group or HIV- group could statistically and significantly interfere with suicidal ideations 
scores. Results found, showed that even if the perceived stress and frequencies of anxiety and depression 
were the same in our study group, the group to which one individual would belong would still be statistically 
significant to the severity of suicidal ideations (β = - 0.23; P = 0.02), as demonstrated in Table 4. 
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Table 4. Multiple linear regression model of psychological parameters and suicidal ideation scores between 
HIV+ and HIV- patients. 
 B (C.I.: 95%) Beta t p 
Study group 
Age 
Gender 
Occupational status 
PSS-10 scores 
HAS scores 
HDS scores 
-3.80 (-7.00; -.60) -0.23 -2.37 0.02 
0.10 (-.015; 0.35) 0.08 0.80 0.42 
1.14 (-2.77; 5.04) 0.05 0.58 0.56 
1.80 (-1.80; 5.40) 0.09 0.99 0.32 
-0.03 (-0.30; 
0.25) 
-0.02 -0.21 0.83 
4.89 (1.51; 8.27) 0.30 2.89 0.00 
7.26 (3.50; 
11.02) 
0.41 3.86 0.00 
Model: R = 0.68; R2 = 0.48; R2 adjusted = 0.40; p <0.05. 
 
4.5. Clinical and demographic description of the group of HIV+ patients in relation with suicidal ideations 
(BSS scores) 
Since there was a significant difference on suicidal ideations between HIV+ and HIV- heroin users, it was 
further investigated intrinsic factors of HIV+ patients correlates of suicide described in literature (respectively 
to general population) in order to better identify risk factors in HIV+ heroin users. Single individuals, younger 
people, men and injecting drug users have been showing higher suicidal risk; hence one way ANOVA, 
student´s t test and Pearson correlation were conducted in order to see the influence of these factors on 
suicidal ideations. No statistically significant effects of gender, marital state, age or routes of transmission 
of HIV in the suicidal ideations gathered through BSS scores were detected in HIV+ heroin users, as shown 
in Table 5. 
 
4.6. Psychiatric diseases, lifetime history of suicide and suicidal ideations in HIV+ patients 
In order to examine the influence of psychiatric disorders and previous suicide attempts ideation that have 
been associated to suicide in suicidal ideation among HIV+ patients, frequencies of psychiatric disorders 
and student´s t test of HIV+ patients with a history of psychiatric disorders and those with no history of 
psychiatric disorders were computed. 42.3% had a diagnosis of a psychiatric disease throughout their lives. 
24% of the patients with psychiatric disorders were taking anti-depressants. However, no statistically 
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significant differences in suicidal ideation scores between individuals with a psychiatric disease reported 
(11.9 ± 10.2) compared to those with no psychiatric disease reported (7.0 ± 8.2) were found; [t (35) = -
1.53; p = 0.13; Cohen´s “d” = 0.53]. Nevertheless, a significant difference in current suicidal ideation 
scores between individuals with one previous suicide attempt (13.7 ± 9.2) and those with no past suicide 
history  (4.9 ± 7.1) was detected [t (35) =- 3.298.  p = 0.002; Cohen “d” = 1.1], as shown in Figure 4. 
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Figure 4. BSS scores between participants with and without previous suicide attempt in HIV+ patients. 
 
  
P = 0.002** 
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Table 5. Demographic and clinical description of the HIV+ patients. 
 
  
Variable N/ (%/SD) Cohen’s “d”/ 
Pearson´s “r” 
p-value of differences 
between groups in (or 
correlation with) BSS 
scores 
 Male 30 (81.1%) 0.36 n.s 
 Age 42 (±4) -0.25 n.s. 
Marital status   
 Single 26 (70.3%)   
 Widower 1 (2.7%) 0.98 n.s. 
 Divorced 9 (24.3%)   
 Married 1 (2.7%)   
Have children     
 Yes 16 (43.2%) 0.41 n.s. 
 No 21 (56.8%)   
Live alone     
 Yes 7 (18.9%)   
 No 30 (81.1%) 0.51 n.s. 
     
Time since disclosure 11.2 (±5.8) 0.02 n.s 
Heterossexual 36 (97.2%) - n.a 
Previous suicide attempt    
 Yes                                   15 (40.5%) 1.01 0.00* 
 No 22 (59.5%)   
Route of transmission   
 Shared needles 21 (58.3%)   
 Sexual 7 (19.4%) 0.14 n.s. 
 Unknown 8 (22.2%)   
HAART  37 (100%) - n.a 
Time on HAART 7.4 (±5.9) -0.39 0.02* 
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4.7. Perceived stress scores and suicidal ideation in HIV+ heroin users 
In order to explore a relation between self –reported stress (PSS-10) and suicidal ideation (BSS) in HIV 
heroin users since perceived stress might be associated to suicidality and simultaneously has been found 
as being associated to HIV infection, a Pearson correlation coefficient was computed. A positive correlation 
between both was found, meaning that the higher the patients perceived stress, the higher the frequency of 
suicidal ideation found in this group (r = 0.37; p = 0.02), as shown in Figure 5. 
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Figure 5. Correlation between BSS scores and PSS-10 scores. 
 
4.8. Comparison of suicidal ideation in HIV+ heroin users presenting depression or presenting “no” 
depression  
Since depression has been correlated with suicide in literature and showed high frequency (38.7%) in HIV+ 
group in the present study, it was performed student´s t test for those who were classified as presenting 
depression and those who had scores compatible with “no” depression in HDS in order to examine the 
effect of depression on suicidal ideation on HIV+ heroin users. Results showed a significant difference in 
suicidal ideation scores between those with depression (15.1 ± 8.3) compared to those with “no” 
depression (4.5 ±6.9), in that higher suicidal ideation scores were found in the group of depression [t (35) 
= -4.2; p=0.000 Cohen “d” = 1.39], as represented in Figure 6. 
r = 0.368 
p=0.02* 
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Figure 6. BSS scores between individuals classified as with or without depressive symptoms (HDS) in HIV+ 
patients. 
 
4.9. Comparison of suicidal ideation in HIV+ heroin users presenting anxiety or presenting “no” anxiety 
Similarly, individuals were categorized as “yes” or “no” anxious based on HAS so as to examine the effect 
of anxiety on suicidal ideation in HIV+ heroin users. Results revealed that those participants classified as 
anxious had statistically significantly higher suicidal ideations scores (13.6 ± 9.0) compared to those with 
“no” anxiety (4.1 ± 6.4); [t (35) = -3.7; p= 0.001; Cohen’s “d” = 1.21], as seen in Figure 7. 
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Figure 7. BSS scores between individuals classified as with or without anxiety symptoms (HAS) among 
HIV+ group. 
  
p = 0.000*** 
P=0.001** 
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4.10. Relation between salivary cortisol concentration and suicidal ideation scores among HIV+ heroin 
users 
Since stress is a risk factor of suicide described in literature in both HIV+ patients and injecting drug users 
and cortisol levels have been showing association with suicidality is some studies, it was examined if there 
was an association of cortisol levels and suicidal ideations in HIV+ heroin users. To explore a possible 
relation between cortisol levels and suicidal ideation, a Pearson correlation was performed. It was found a 
positive correlation between both (r = 0.42; p = 0.01), as shown in Figure 8. 
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Figure 8. Correlation between salivary cortisol levels and BSS scores. 
 
4.11. Multiple linear regression model of predictors for suicide among HIV+ heroin users 
Based on variables that showed relation with suicidal ideation scores among HIV+ patients in the present 
study, we made a multiple linear regression, wherein we found three parameters that could significantly 
predict suicide ideations measured by BSS scores, namely: previous suicide attempt (β = 0.29, p = 0.03), 
salivary cortisol levels (β = 0.44, p = 0.00) and HAD (β = 0.45, p = 0.00). Taken together, the model 
drawn from variables predicts a significant increase in the scores of suicidal ideation, as represented in 
Table 6. 
  
r = 0.42;   
p = 0.01* 
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Table 6. Multiple linear regression model of variables related to suicide in HIV+ patients. 
BSS B (C.I.: 95%) Beta t p 
HAS 
 
3.38 (-2.15; 8.90) 0.19  1.25 0.22 
HDS 
 
8.19 (2.59; 13.80) 0.45  3.00 0.00 
Cortisol 
7.91 (3.19; 12.63) 0.44  3.44 0.00 
PSS-10 
-0.07 (-0.57; 0.38) -0.05 -0.31 0.76 
Previous suicide 
attempt 
5.25 (0.57; 9.92) 0.29  2.30 0.03 
Model: R= 0.80; R2 = 0.64; R2 adjusted = 0.58. P <0.05. 
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5. DISCUSSION 
 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
41 
 
5.1. Comparison of suicidal ideation between HIV+ and HIV- heroin users 
We aimed to investigate suicidality among HIV+ heroin users through a comparative study with HIV - heroin 
users. Statistically significant higher suicidal ideation scores were found in the group of HIV+ compared to 
HIV- patients. This result is not in agreement with a similar study by Jin et al 2013, addressing suicide 
across heroin users in the context of HIV infection, wherein no differences in suicidal ideations were found 
by comparing HIV+ patients with HIV- patients. Nevertheless, the higher rates of suicidal ideations in the 
group of HIV+ patients in the present study suggests that not only does HIV infection increase the risk of 
suicide compared to general population from different settings as reported in previous studies (Aldaz et al., 
2011) (Jin et al., 2006) (Govender & Schlebusch, 2012), but it may also represent additional risk of 
suicide among injecting drug users. Notwithstanding, the sequential multiple linear regression model made 
in the present study predicting suicidal ideation from socio-demographic and psychological variables 
usually associated with suicide, showed that when socio-demographic variables like age, gender, 
occupational status were taken into account the difference on suicidal ideation between HIV+ and HIV- 
individuals was still present. This means meaning that the difference on suicidal ideation between the two 
populations was not due to the differences on the socio-demographic variables between the two study 
populations. Interestingly, in the same sequential multiple linear regression model, when the psychological 
parameters usually correlated to suicide were considered, the significance of the group to which one 
individual in the study population belonged was maintained. Apparently, in our study population neither 
perceived stress nor depression or anxiety were relevant factors behind the influence of being HIV+ or HIV- 
heroin user on suicidal ideation. 
 
5.3. Comparison of social, demographic and clinical factors associated to suicide between HIV+ and HIV- 
heroin users  
The sequential regression model made showed that if age, gender and occupational status were 
homogeneous between the two groups, the HIV status would still be a significant predictor of suicidal 
ideation. We compared these variables and others also previously reported to be associated to suicide in 
our study population to investigate if relevant differences were present between the two groups. No 
statistically significant differences were found in other social factors usually associated to predisposition to 
psychosocial stress across HIV+ and HIV- patients, such as marital status, alcoholic or smoking habits. 
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Similarly, no statistically significant differences in clinical factors commonly found in individuals with 
records of suicide attempts such as psychiatric disorder and familiar history of suicide between two groups 
were detected. None-the- less, no statistically significant differences were found either in the frequency of 
anxiety or depression symptoms (based on HADS scores) across the two groups. These findings were not 
parallel to others reported regarding depression (Kelly et al., 1998), or anxiety (Morrison et al., 2002) as 
well as in the self-reported stress wherein these parameters were found as being higher in HIV+ patients 
when they are compared to general population. However, considering that the study population is 
composed of drug users, these results are in line with others studies that show high frequency of 
psychiatric conditions in both HIV+ patients and drug users (Grassi et al., 2001), though the type of injected 
drug used was not discriminated. This finding is also supported by other authors that postulate that some 
situations experienced by both injecting drug users and HIV+ patients might render them more likely to 
develop psychiatric disorders (Sarin, Singh, Samson, & Sweat, 2013), namely: absence of social support, 
unemployment, homelessness in the first group against social isolation, discrimination and occupational 
difficulties due to HIV infection (Kelly et al., 1998) in the second. Indeed, in the present study, study 
population was mostly composed of unemployed, single men irrespectively to diagnosis of HIV. However, 
the absence of differences in psychological measures and socio-demographic across groups, suggests that 
the additional effect of the HIV infection increasing suicidal risk among injecting drug users might 
eventually be explained by alterations related with the HIV and the immune response to the virus.  
 
5.2. Comparison of frequencies of past suicide attempt between HIV+ and HIV- heroin users 
Since in previous studies individuals with a past history of suicide were found to be more likely for new 
attempts of suicide (Kelly et al., 1998), we examined whether or not there could be differences on history 
of suicide attempt between groups. Our results showed that among heroin users, 40.5% of HIV+ and 30.9% 
of HIV- had attempted suicide at least once in their lifetime and the variation was not statistically significant. 
This result is in accordance with results reported by Malbegiere & De Andrade, 2001 wherein by analyzing 
suicidality between HIV+ and HIV- drug users, no statistically significant differences were found. But still, 
these high frequencies in both groups show that heroin users are very likely to attempt suicide regardless 
HIV diagnosis, what is consistent with literature that describes injecting drugs use as an important risk 
factor for suicide (Sarin et al., 2013) and is replicated in the study by Jin et al 2013 that also included a 
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healthy control and found statistically significant differences in suicidal ideation scores among the two 
groups of drug users (both HIV+ and HIV-) when compared to healthy individuals. Withal, the absence of 
statistically significant differences in the frequency of previous suicide attempt in the present study may 
arise from the fact that the attempt in this study was considered during lifetime history, meaning that it is 
possible that the attempt might have occurred before the HIV infection when groups analyzed would have 
been in the same condition of HIV status. 
 
5.4. Association between psychological measures (anxiety and depression scores), previous suicide 
attempts and suicide ideation scores among HIV+ heroin users 
Although there were no differences in clinical and psychological measures between HIV+ and HIV- patients, 
we further analyzed the influence of these variables on suicidal ideation in HIV+ patients, in order to obtain 
information that could be of relevance to draw interventional plans to reduce the risk of suicide in HIV+ 
heroin users. Among patients infected with HIV when analyzed separately, the results found revealed that 
those participants classified as presenting depression in HDS scores had statistically significant higher 
suicidal ideation scores compared to those classified as presenting “no” depression, what is consistent 
with the literature that shows an important role of depression increasing the risk of suicide across patients 
infected with HIV (Bragança & Palha, 2011). Suicidal ideation scores were found higher in individuals 
classified as presenting anxiety as well, after dichotomized in “yes” or “no” anxious based on HAS scores. 
These results show that anxiety and depression symptoms are a concern among HIV+ patients and play an 
important role increasing suicidal risk in HIV+ patients who are concomitantly heroin users. 
Participants  HIV+ showed a difference in the scores of suicidal ideation relatively to past suicide attempts 
that was significant, in which those with a lifetime history of suicide had higher suicidal ideation scores 
compared to those who had never attempted, suggesting that mechanisms that lead to suicide may be 
enduring and constitute a factor of vulnerability to individuals. This is consistent with several evidences 
showing people who attempted suicide once, are more likely to attempt again compared to those with no 
past history of suicide (Kinyanda et al., 2011) .  
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5.4. Correlation between risk and chronologic factors of HIV infection and suicide among HIV+ heroin 
users 
Regarding risk behavior associated to HIV infection, the most frequently route of transmission of HIV 
reported by participants was by sharing needles. Even though the route of transmission was not associated 
with suicidality in the present study, this result highlights the need of intensifying the mechanisms to 
reduce this practice among people with risk behavior. No correlation was found between time of disclosure 
of HIV infection and time since suicide attempt, what differs of what is reported in WHO 2000, pointing 
suicide attempts as more frequently occurring by the time of diagnosis or a few months later. Curiously, it 
supports the study by Haastrecht et al, 1995 that found no independent effect of disclosure of HIV 
infection inducing suicide, as far as HIV+ injecting drug users are concerned. By reacting differently to a 
disclosure of HIV infection than general population, this result suggests that the appraisal of threat 
associated to HIV infection might differ in injecting drug users compared to the general population. 
However, we only considered the time of last attempt of suicide and it is possible that the individuals might 
have tried to kill themselves several times after disclosure; thus, if we had considered the time of first 
attempt of suicide rather than the time of last attempt of suicide, it could have been more informative. No 
correlation was found with time of disclosure and suicidal ideation as well. Meanwhile, a negative 
correlation was found between time on HAART and current suicidal ideation (r = -0.40; p = 0.02; df = 32). 
That is, patients that initiated HAART more recently have more thoughts about suicide. If we consider a low 
immunity as criteria for initiating HAART, one may speculate that low levels of CD4+ T lymphocytes might 
be related to suicidal ideation. But still, an adaptation to treatment is another aspect to be considered. 
 
5.5. Correlation between stress (cortisol levels and PSS-10 scale scores) and suicidal ideations among 
HIV+ heroin users 
Even though the psychological parameters were associated to suicide ideation among HIV+ group, they 
might not explain all the effect on suicidal ideation since no differences in psychological measures were 
found between them and HIV- patients, as aforementioned. Since stress has been associated to suicide and 
cortisol level is an available biological marker of stress, we further explored if there was a relation between 
cortisol level and suicide ideation among HIV+ heroin users. To examine a possible relation between salivary 
cortisol level and suicidal ideation, a Pearson correlation was performed. Our results revealed that cortisol 
levels had a positive correlation with BSS scores in HIV+ heroin users. This finding is consistent with the 
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study by Chatzifittofis 2013 that found higher cortisol levels in suicide attempters, compared with healthy 
volunteers. Yet to this state of knowledge studies addressing cortisol levels in suicide, either in the context 
of heroin users or HIV+ patients, are lacking, hence comparison with studies in groups with similar 
characteristics could not be made. Equally, self-reported stress scores correlated positively with suicidal 
ideation scores. That is, participants who appraised their lives as stressful during previous month had more 
thoughts of suicide what is in line with literature that described high perceived stress scores among HIV+ 
patients (Su et al., 2013), still the high scores were associated to other psychological measures but 
suicide. Actually, existing studies related to perceived stress and suicide either used different scales to 
measure perceived stress, or evaluated a different psychological parameter that might in turn be 
associated to suicide. In addition to this, again studies applying the PSS-10 scale to analyze suicide in HIV+ 
heroin users are lacking and these comparisons are not considering the specific characteristics of this 
group.  
Cortisol levels were not associated neither with anxiety scores [t (31) = -1.27; p = 0.21; df = 0.42], nor 
with depression scores [t (31) = 0.60; p = 0.55; df = 0.21]. This finding is not in agreement with published 
evidence showing that depression is correlated with cortisol levels. Still, these correlations were found in 
patients with other psychiatric disorders, such as women with major depression (Geoffroy, Hertzman, Li, & 
Power, 2013) or bipolar disorder (Kamali, Saunders, Prossin, & Brucksch, 2013) and none of them 
included HIV+ patients concomitantly using injected drugs. Moreover, cortisol levels did not correlate with 
perceived stress as well. Apparently, although participants appraise their lives as stressful it does not 
correlate with the cortisol release. This is consistent with other studies wherein no correlation between the 
two variables was found (Faresjö et al., 2013). One possible explanation to this absence of correlation 
would be that because of the effects of both heroin and HIV in the Central Nervous System, one may think 
that the appraisal of the individuals might be affected by alterations in cognition. However, to better clarify 
it would be necessary to screen altered cognition but no measures were applied to this purpose in the 
present study.  
 
Study limitations 
This study had some limitations that should be acknowledged. Firstly, our study population was recruited 
by convenience. Secondly, a longitudinal study could be more conclusive in the context of causality. Third, 
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some information that we intended to include in analysis regarding clinic variables was missing. Finally, 
study was restricted to heroin users, thus results might not be applied neither to other drugs users nor to 
other HIV+ patients. Still, by working with a more homogeneous group, the effects of variability between 
groups to consider in analysis were reduced. 
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6. CONCLUSIONS 
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Our findings revealed that besides being a population with several risk factors accounting for suicide, HIV 
infection increased the risk compared to HIV- heroin users. Higher scores of anxiety and depression were 
associated with higher suicidal ideation scores among HIV+ patients. These variables together with 
perceived stress showed to play an important role in suicidal ideation among HIV+ heroin users, highlighting 
the importance of screening and treating psychiatric disorders in order to reduce the risk of suicide and 
suffering among these patients. Previous suicide attempt was associated with suicidal ideation, what is 
consistent with other literature addressing correlates to suicidal ideation in general population. Once no 
statistically significant differences in past suicide history were found across HIV+ and HIV- participants, the 
finding emphasizes the need of intensifying suicidal screening among heroin users irrespectively to HIV 
infection. Together with psychiatric disorders and aforementioned results, in the model of regression made, 
cortisol levels showed to be a good predictor of suicide ideation among HIV+ patients that are heroin drug 
users, replicating results of other published studies, though in a study population with different settings. 
This finding suggests that cortisol might be a potential variable to further explore as a biological tool to be 
either accessed or manipulated in the management of suicidality. 
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7. FINAL REMARKS AND FUTURE 
RESEARCH PERSPECTIVES 
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This work was thought to contribute to emphasize the need of more efficient interventional plans focused 
on screening suicide ideation among HIV+ heroin users. While suicide is unpredictable, people might benefit 
of any reduction in psychiatric disorders prevalence to both partially control the suicide risk and reduce 
suffering associated to diseases. Notwithstanding, important aspects of treatment such as adherence to 
HAART and prevention of transmission of HIV infection might be improved by reducing the frequency of 
psychiatric disorders as well.  
  
Replicate findings in more heterogeneous groups from different settings may amplify the utility of the 
results and simultaneously increase their reliability.  
Moreover, respectively to HIV infection, some immunologic parameters are suggested to be associated to 
psychiatric disorders such as CD4+ T lymphocyte counts, CD8+ T lymphocyte and the RNA viral load (VL). 
Since literature suggests an association between the HPA axis dysregulation and immune activation as 
influencing behavior, analyzing these parameters in association with the cortisol levels could hence be 
worthy to investigate other mechanisms through which HIV infection could be influencing suicidal risk.  
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HS SALIVARY CORTISOL EIA KIT
Intended Use
The Salimetrics™ cortisol kit is a competitive immunoassay specifically 
designed and validated for the quantitative measurement of salivary cor-
tisol. It is intended only for research use in humans and some animals. 
Please read the complete kit insert before performing this assay. Fail-
ure to follow kit procedure and recommendations for saliva collection 
and sample handling may result in false values. 
For further information about this kit, its application, or the procedures 
in this insert, please contact the technical service team at Salimetrics or 
your local sales representative.
Introduction
Cortisol (hydrocortisone, Compound F) is the major glucocorticoid 
produced in the adrenal cortex. (1) Cortisol production has a circadian 
rhythm, (2,3) with levels peaking in the early morning and dropping 
to lowest values at night. (4,5) Levels rise independently of circadian 
rhythm in response to stress. (6)
In blood, only about 5-10% of cortisol is in its unbound or biologi-
cally active form. The remaining cortisol is bound to serum proteins. 
(7) Unbound serum cortisol enters saliva via intracellular mechanisms; 
in saliva, the majority of cortisol remains unbound to protein. Salivary 
cortisol levels are unaffected by salivary flow rate and are relatively 
resistant to degradation from enzymes or freeze-thaw cycles. (8,9)
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Studies consistently report high correlations between serum and salivary 
cortisol, indicating that salivary cortisol levels reliably estimate serum 
cortisol levels. (10-12)
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Test Principle
A microtitre plate is coated with monoclonal antibodies to cortisol. 
Cortisol in standards and unknowns competes with cortisol linked to 
horseradish peroxidase for the antibody binding sites. After incubation, 
unbound components are washed away. Bound cortisol peroxidase is 
measured by the reaction of the peroxidase enzyme on the substrate 
tetramethylbenzidine (TMB). This reaction produces a blue color. A 
yellow color is formed after stopping the reaction with sulfuric acid. 
Optical density is read on a standard plate reader at 450 nm. The amount 
of cortisol peroxidase detected, as measured by the intensity of color, is 
inversely proportional to the amount of cortisol present. (13)
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pH Indicator
A pH indicator in the assay diluent alerts the user to samples with high or low 
pH values. Acidic samples will turn the diluent yellow. Alkaline samples will 
turn the diluent purple. Dark yellow or purple wells indicate that a pH value 
for that sample should be obtained using pH strips. Cortisol values from 
samples with a pH ≤ 3.5 or ≥ 9.0 may be artificially inflated or lowered. (14)
Storage
All components of this kit are stable at 2-8°C until the kit’s expiration date.
Safety Precautions 
• Liquid stop is a 3-molar solution of sulfuric acid. This solution is caus-
tic; use with care. 
• See “Material Safety Information” at the end of procedure.
• A safety data sheet is available on request.
Materials Needed But Not Supplied 
• Precision pipette to deliver 15 and 25 μL 
• Precision multichannel pipette to deliver 50 μL and 200 μL 
• Vortex 
• Plate rotator with 0.08-0.17 inch orbit capable of 500 rpm 
       (if unavailable, tap plate to mix)
• Plate reader with a 450 nm filter 
• Log-linear graph paper or computer software for data reduction 
• Deionized water 
• Reagent reservoirs 
• One disposable polypropylene tube to hold at least 24 mL 
• Pipette tips 
• Serological pipette to deliver up to 24 mL
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Materials Supplied with Single Kit
Item Quantity/Size
1 Microtitre PlateCoated with monoclonal anti-cortisol antibodies. 1/96-well
2
Cortisol Standards
In a saliva-like matrix. Ready to use, traceable to 
NIST standard: 3.0, 1.0, 0.333, 0.111, 0.037, 0.012
μg/dL (82.77, 27.59, 9.19, 3.06, 1.02, 0.33 nmol/L).
Contain: cortisol, buffer, preservative.
6 vials/500 μL         
each
3
Cortisol Controls
High, Low, in a saliva-like matrix. Ready to use.
Contain: cortisol, buffer, preservative.
2 vials/500 μL 
each
4
Wash Buffer Concentrate (10X)
Dilute before use according to Reagent Preparation.
Contains: phosphate buffer, detergent, preservative.
1 bottle/100 mL
5 Assay DiluentContains: phosphate buffer, pH indicator, preservative. 1 bottle/60 mL
6
Cortisol Enzyme Conjugate
Concentrate. Dilute before use with assay diluent.
(See step 5 of Procedure.) 
Contains: cortisol conjugated to HRP, preservative.
1 vial/50 μL
7 TMB Substrate SolutionNon-toxic, ready to use. 1 bottle/25 mL
8 3 M Stop SolutionContains: sulfuric acid. 1 bottle/12.5 mL
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Non-Specific Binding (NSB) Wells
Do not contain anti-cortisol antibody. Break off and 
insert as blanks (optional) where needed.
1 strip
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Specimen Collection
Avoid sample collection within 60 minutes after eating a major meal or 
within 12 hours after consuming alcohol. Bovine hormones normally 
present in dairy products can cross-react with anti-cortisol antibodies 
and cause false results. Acidic or high sugar foods can compromise 
assay performance by lowering sample pH and influencing bacterial 
growth. To minimize these factors, rinse mouth thoroughly with water 
10 minutes before sample is collected.
Donors may collect whole saliva by tilting the head forward, allowing 
the saliva to pool on the floor of the mouth, and then passing the saliva 
through the Saliva Collection Aid, Item No. 5016.02, into a polypro-
pylene vial. Collection protocols are available upon request or online 
at www.salimetrics.com. Samples from adults and from children ages 6 
and above may also be collected using the SalivaBio Oral Swab (SOS), 
Item No. 5001.02. Samples from children under the age of 6 may be 
collected with the SalivaBio Children’s Swab (SCS), Item No. 5001.06. 
The SalivaBio Infant’s Swab (SIS), Item No. 5001.08, is available for 
use with children under the age of 6 months.
Samples visibly contaminated with blood should be recollected. We 
recommend that samples be screened for possible blood contamination 
(15,16) using a reliable screening tool such as the Salimetrics Blood 
Contamination EIA Kit (Item Nos. 1-1302/1-1302-5). Do not use dip-
sticks, which result in false positive values due to salivary enzymes.
It is important to record the time and date of specimen collection when 
samples are obtained due to the diurnal variation in cortisol levels.
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Sample Handling and Preparation
After collection it is important to keep samples cold, in order to avoid 
bacterial growth in the specimen. Refrigerate samples within 30 min-
utes, and freeze at or below -20°C within 4 hours after collection. 
(Samples may be stored at -20°C or lower for long-term storage.)
Do not add sodium azide to saliva samples as a preservative, as it may 
cause interference in the immunoassay.
Freezing saliva samples will precipitate mucins. On day of assay, 
thaw the saliva samples completely, vortex, and centrifuge at 1500 x g 
(@3000 rpm) for 15 minutes. Centrifuging removes mucins and other 
particulate matter which may interfere with antibody binding, leading to 
falsely elevated results. Samples should be at room temperature before 
adding to assay plate. Pipette clear sample into appropriate wells. Re-
freeze saliva samples as soon as possible after adding to the assay plate. 
Centrifuge/re-centrifuge saliva samples each time that they are thawed. 
Avoid multiple freeze-thaw cycles.
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General Kit Use Advice 
• This kit uses break-apart microtitre strips. You may run less than a 
full plate. Unused wells must be stored at 2-8°C in the sealed foil 
pouch with desiccant and used in the frame provided. 
• The quantity of reagent provided with a single kit is sufficient for 
three partial runs. The volumes of wash buffer and conjugate pre-
pared for assays using less than a full plate should be scaled down 
accordingly, keeping the same dilution ratio. 
• Do not mix components from different lots of kits. 
• When using a multichannel pipette, reagents should be added to 
duplicate wells at the same time. Follow the same sequence when 
adding additional reagents so that incubation time with reagents is 
the same for all wells. 
• To ensure highest quality assay results, pipetting of samples and 
reagents must be done as quickly as possible (without interruption) 
across the plate. Ideally, the process should be completed within 20 
minutes or less. 
• When running multiple plates, or multiple sets of strips, a standard 
curve must be run with each individual plate and/or set of strips. 
• The temperature of the laboratory may affect assays. Salimetrics’ 
kits have been validated at 68-74ºF (20-23.3ºC). Higher or lower 
temperatures will cause an increase or decrease in OD values, 
respectively. Salimetrics cannot guarantee test results outside of this 
temperature range. 
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• Avoid microbial contamination of opened reagents. Salimetrics 
recommends using opened reagents within one month. Store all 
reagents at 2-8°C. 
• Routine calibration of pipettes is critical for the best possible assay 
performance.
Reagent Preparation
• Bring all reagents to room temperature and mix before use. A mini-
mum of 1.5 hours is necessary for the 24 mL of assay diluent used 
in Step 5 (conjugate dilution) to come to room temperature. 
• Bring microtitre plate to room temperature before use. It is impor-
tant to keep the zip-lock pouch with the plate strips closed until 
warmed to room temperature, as humidity may have an effect on 
the coated wells. 
• Prepare 1X wash buffer by diluting wash buffer concentrate 10-fold 
with room-temperature deionized water (100 mL of 10X wash buf-
fer to 900 mL of deionized H2O). Dilute only enough for current 
day’s use, and discard any leftover reagent. (If precipitate has 
formed in the concentrated wash buffer, it may be heated to 40°C 
for 15 minutes. Cool to room temperature before use in assay.)
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Procedure
Step 1: Determine your plate layout. Here is a suggested layout.
 1 2 3 4 5 6 7 8 9 10 11 12
A 3.000 Std 3.000 Std Ctrl-H Ctrl-H         
B 1.000 Std 1.000 Std Ctrl-L Ctrl-L         
C 0.333 Std 0.333 Std Unk-1 Unk-1         
D 0.111 Std 0.111 Std Unk-2 Unk-2         
E 0.037 Std 0.037 Std Unk-3 Unk-3         
F 0.012 Std 0.012 Std Unk-4 Unk-4         
G Zero Zero Unk-5 Unk-5         
H NSB* NSB* Unk-6 Unk-6         
  *NSB = Non-specific binding wells.  These may serve as blanks. Use is optional.
Step 2: Keep the desired number of strips in the strip holder and place 
the remaining strips back in the foil pouch. If you choose to place non-
specific binding wells in H-1, 2, remove strips 1 and 2 from the strip 
holder and break off the bottom wells. Place the strips back into the strip 
holder leaving H-1, 2 blank. Break off 2 NSB wells from the strip of 
NSBs included in the foil pouch. Place in H-1, 2. Alternatively, NSBs 
may be placed wherever you choose on the plate. Reseal the zip-lock 
foil pouch containing unused wells and desiccant. Store at 2-8°C.
Cautions: 1. Extra NSB wells should not be used for determination of  
                     standards, controls or unknowns.
     2. Do not insert wells from one plate into a different plate.
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Step 3: Pipette 24 mL of assay diluent into a disposable tube. Set aside 
for Step 5.
Step 4: 
• Pipette 25 μL of standards, controls, and unknowns into appropri-
ate wells. Standards, controls, and unknowns should be assayed in 
duplicate. 
• Pipette 25 μL of assay diluent into 2 wells to serve as the zero value. 
• Pipette 25 μL of assay diluent into each NSB well.
Step 5: Make a 1:1600 dilution of the conjugate by adding 15 μL of 
the conjugate to the 24 mL of assay diluent prepared in Step 3. (Scale 
down proportionally if not using the entire plate.) Conjugate tube may 
be centrifuged for a few minutes to bring the liquid down to the tube 
bottom. Immediately mix the diluted conjugate solution and pipette 200 
μL into each well using a multichannel pipette.  Make note of any wells 
with dark yellow or purple pH indicator changes (see description of pH 
indicator, p. 3).
Step 6: Mix plate on rotator for 5 minutes at 500 rpm (or tap to mix) and 
incubate at room temperature for an additional 55 minutes. 
Step 7: Wash the plate 4 times with 1X wash buffer. A plate washer 
is recommended. However, washing may be done by gently squirting 
wash buffer into each well with a squirt bottle, or by pipetting 300 μL of 
wash buffer into each well, and then discarding the liquid by inverting 
the plate over a sink. After each wash, the plate should be thoroughly 
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blotted on paper towels before being turned upright. If using a plate 
washer, blotting is still recommended after the last wash, just before 
the addition of the TMB.
Step 8: Add 200 μL of TMB solution to each well with a multichannel 
pipette.
Step 9: Mix on a plate rotator for 5 minutes at 500 rpm (or tap to mix) 
and incubate the plate in the dark at room temperature for an additional 
25 minutes.
Step 10: Add 50 μL of stop solution with a multichannel pipette.
Step 11: 
• Mix on a plate rotator for 3 minutes at 500 rpm (or tap to mix).
       Caution: Spillage may occur if mixing speed exceeds 600 rpm. 
• Wipe off bottom of plate with a water-moistened, lint-free cloth and 
wipe dry. 
• Read in a plate reader at 450 nm. Read plate within 10 minutes of 
adding stop solution. (Correction at 490 to 630 nm is desirable.) 
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Quality Control
The Salimetrics’ high and low salivary cortisol controls should be run 
with each assay. The control ranges established at Salimetrics are to be 
used as a guide. Each laboratory should establish its own range. Varia-
tions between laboratories may be caused by differences in techniques 
and instrumentation.
Calculations
1.   Compute the average optical density (OD) for all duplicate wells.
2.   Subtract the average OD for the NSB wells (if used) from the aver-  
      age OD of the zero, standards, controls, and unknowns.
3.   Calculate the percent bound (B/Bo) for each standard, control, and  
      unknown by dividing the average OD (B) by the average OD for the  
      zero (Bo). (The zero is not a point on the standard curve.)
4.   Determine the concentrations of the controls and unknowns by  
      interpolation using software capable of logistics. We recommend   
      using a 4-parameter non-linear regression curve fit.
5.   Samples with cortisol values greater than 3.0 μg/dL (82.77 nmol/L)   
      should be diluted with assay diluent and rerun for accurate results.  
      If a dilution of the sample is used, multiply the results by the dilu- 
      tion factor. 
      When running multiple plates, or multiple sets of strips, a standard 
      curve must be run with each individual plate and/or set of strips.
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Assay Summary
1. Bring all reagents to room temperature 
and mix before use.
2. Bring plate to room temperature and 
prepare for use with NSB wells. (Use of 
NSB wells is optional.)
3. Prepare 1X wash buffer.
4. Prepare tube with 24 mL of assay dilu-
ent for conjugate dilution, which will be 
made later.
5. Pipette 25 μL of standards, controls, and 
unknowns into appropriate wells.
6. Pipette 25 μL of assay diluent into zero 
and NSB wells.
7. Make 1:1600 dilution of conjugate 
(15 μL into 24 mL assay diluent), mix, 
13
and immediately pipette 200 μL into 
each well.  Note any pH indicator color 
changes.
8. Mix plate for 5 minutes at 500 rpm. 
Incubate for an additional 55 minutes at 
room temperature.
9. Wash plate 4 times with 1X wash buffer. 
Blot.
10. Add 200 μL TMB solution to each well.
11. Mix plate for 5 minutes at 500 rpm. In-
cubate in dark at room temperature for 
25 additional minutes.
12. Add 50 μL stop solution to each well. 
Mix for 3 minutes at 500 rpm.
13. Wipe plate bottom clean and read within 
10 minutes of adding stop.
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Typical Results
The following chart and graph are for illustration only and should not 
be used to calculate results from another assay.
Well Sample Average OD B B/Bo 
Cortisol 
(μg/dL)
A1,A2 S1 0.094 0.071 0.048 3.000 
B1,B2 S2 0.236 0.213 0.145 1.000 
C1,C2 S3 0.524 0.501 0.340 0.333 
D1,D2 S4 0.897 0.874 0.593 0.111 
E1,E2 S5 1.219 1.196 0.812 0.037 
F1,F2 S6 1.379 1.356 0.921 0.012 
G1,G2 Bo 1.496 1.473 NA NA 
H1,H2 NSB 0.023 NA NA NA 
Example: HS Cortisol 4-Parameter Curve Fit
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Material Safety Information*
Hazardous Ingredients
Liquid stop solution is caustic; use with care. We recommend the proce-
dures listed below for all kit reagents. MSDS sheets are available from 
Salimetrics upon request.
Handling
Follow good laboratory procedures when handling kit reagents. Labora-
tory coats, gloves, and safety goggles are recommended. Wipe up spills 
using standard absorbent materials while wearing protective clothing. 
Follow local regulations for disposal.
Emergency Exposure Measures
In case of contact, immediately wash skin or flush eyes with water for 
15 minutes. Remove contaminated clothing. If inhaled, remove indi-
vidual to fresh air. If individual experiences difficulty breathing, give 
oxygen and call a physician.
*The above information is believed to be accurate but is not all-inclu-
sive. This information should be used only as a guide. Salimetrics will 
not be liable for accidents or damage resulting from misuse of product.
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HS Salivary Cortisol EIA Kit Performance Characteristics
Sample Dilution Recovery
Four saliva samples were diluted with assay diluent and assayed.
Sample Dilution Factor Expected 
 (μg/dL) 
Observed  
(μg/dL) 
Recovery
(%) 
S1
 undiluted  N/A 0.73  N/A
1:2 0.37 0.39 107
1:4 0.18 0.20 111
1:8 0.09 0.10 111 
1:16 0.05 0.05 105
S2 
 undiluted  N/A 0.80  N/A
1:2 0.40 0.40 101 
1:4 0.20 0.19 97 
1:8 0.10 0.09 94 
1:16 0.05 0.05 110
S3
undiluted N/A 0.61 N/A
1:2 0.31 0.30 98
1:4 0.15 0.15 101
1:8 0.08 0.08 108
1:16 0.04 0.04 108
S4
undiluted N/A 2.89 N/A
1:2 1.45 1.53 105
1:4 0.72 0.77 106
1:8 0.36 0.42 115
1:16 0.18 0.2 108
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Linearity of Assay
Sample
Samples Avg
Observed Expected RecoveryLow High
a (Low) 100% 0% 0.07 0.07 N/A
b 90% 10% 0.36 0.34 108
c 80% 20% 0.63 0.61 104
d 70% 30% 0.93 0.88 106
e 60% 40% 1.13 1.15 98
f 50% 50% 1.45 1.42 102
g 40% 60% 1.64 1.69 97
h 30% 70% 1.88 1.96 96
i 20% 80% 2.27 2.23 102
j 10% 90% 2.49 2.50 99
k (High) 0% 100% 2.77 2.77 N/A
Analytical Sensitivity
The lower limit of sensitivity was determined by interpolating the mean 
optical density minus 2 SDs of 10 sets of duplicates at the 0 μg/dL level. 
The minimal concentration of cortisol that can be distinguished from 0 
is 0.007 μg/dL.
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Precision
The intra-assay precision was determined from the mean of 20 replicates 
each.
Sample N Mean 
(μg/dL) 
Standard Deviation 
(μg/dL) 
Coefficient of Variation 
(%)
PS1 20 2.07 0.08 4 
PS2 20 1.14 0.05 4 
PS3 20 0.42 0.01 3
PS4 20 0.16 0.01 5
PS5 20 0.06 0.00 7
The inter-assay precision was determined from the mean of average 
duplicates for 20 separate runs.
Sample N Mean 
(μg/dL) 
Standard Deviation 
(μg/dL) 
Coefficient of Variation 
(%)
PS1 20 1.99 0.05 3
PS2 20 1.16 0.05 4
PS3 20 0.43 0.01 3
PS4 20 0.18 0.01 9
PS5 20 0.06 0.01 11
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Recovery
Five saliva samples containing different levels of endogenous cortisol 
were spiked with known quantities of cortisol and assayed.
Sample Endogenous  
(μg/dL) 
Added 
(μg/dL) 
Expected 
(μg/dL) 
Observed 
(μg/dL) 
Recovery 
(%) 
1 0.071 2.00 2.13 2.20 103
2 0.071 0.20 0.27 0.28 104 
3 0.071 0.04 0.11 0.11 98
4 0.078 2.33 2.25 2.33 103
5 0.078 0.20 0.28 0.31 113 
6 0.080 0.04 0.12 0.12 103 
7 0.86 0.20 1.06 1.16 109 
8 0.89 0.04 0.93 1.02 109
Correlation with Serum
The correlation between serum and saliva cortisol was determined by 
assaying 49 matched samples using the Diagnostic Systems Laborato-
ries serum Cortisol EIA and the Salimetrics HS Salivary Cortisol EIA.
The correlation between saliva and serum was highly significant, 
r (47) = 0.91, p < 0.0001.
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Specificity of Antiserum
Compound Spiked Concentration (ng/mL) 
% Cross-reactivity in HS 
Salivary Cortisol EIA 
Prednisolone 100 0.568 
Prednisone 1000 ND 
Cortisone 1000 0.130 
11-Deoxycortisol 500 0.156 
21-Deoxycortisol 1000 0.041 
17α-Hydroxyprogesterone 1000 ND 
Dexamethasone 1000 19.2 
Triamcinolone 1000 0.086 
Corticosterone 10,000 0.214 
Progesterone 1000 0.015 
17β-Estradiol 10 ND 
DHEA 10,000 ND 
Testosterone 10,000 0.006 
Transferrin 66,000 ND 
Aldosterone 10,000 ND 
  ND = None detected (<0.004)
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Salivary Cortisol Example Ranges
Each laboratory should establish its own range of expected values. The follow-
ing values have been reported for salivary cortisol.
Group Number Overall Range (μg/dL)
Children, neonatal 275 ND - 3.417 
Children, age 6 months 165 ND - 2.734 
Group Number AM Range 
(μg/dL) 
PM Range 
(μg/dL)
Children, ages 2.5-5.5 112 0.034 - 0.645 0.053 - 0.607 
Children, ages 8-11 285 0.084 - 0.839 ND - 0.215 
Adolescents, ages 12-18 403 0.021 - 0.883 ND - 0.259 
Adult males, ages 21-30 26 0.112 - 0.743 ND - 0.308 
Adult females, ages 21-30 20 0.272 - 1.348 ND - 0.359 
Adult males, ages 31-50 67 0.122 - 1.551 ND - 0.359 
Adult females, ages 31-50 31 0.094 - 1.515 ND - 0.181 
Adult males, ages 51-70 28 0.112 - 0.812 ND - 0.228 
Adult females, ages 51-70 23 0.149 - 0.739 0.022 - 0.254 
All adults 192 0.094 - 1.551 ND - 0.359 
Group Number 2300h (ug/dL)
Normal subjects 19 0.007 – 0.115 
Cushing’s subjects 21 0.130 – 2.972 
ND = None detected
Expected ranges for neonates to 5.5 years were derived using the Salimetrics Salivary Cortisol Im-
munoassay Kit.
Expected ranges for 8 to 18 years were reported from an unpublished manuscript, Pennsylvania 
State University’s Behavioral Endocrinology Laboratory.  Adult ranges were obtained from pub-
lished literature. (7)
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Seller’s Limited Warranty
“Seller warrants that all goods sold hereunder will be free from defects in mate-
rial and workmanship. Upon prompt notice by Buyer of any claimed defect, 
which notice must be sent within thirty (30) days from date such defect is first 
discovered and within three months from the date of shipment, Seller shall, at 
its option, either repair or replace the product that is proved to Seller’s satisfac-
tion to be defective. All claims should be submitted in writing. This warranty 
does not cover any damage due to accident, misuse, negligence, or abnormal 
use. Liability in all cases, will be limited to the purchased cost of the kit.
It is expressly agreed that this limited warranty shall be in lieu of all war-
ranties of fitness and in lieu of the warranty of merchantability. Seller shall 
not be liable for any incidental or consequential damages that arise out of 
the installation, use or operation of Seller’s product or out of the breach of 
any express or implied warranties.”
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DECLARAÇÃO DE CONSENTIMENTO INFORMADO 
Considerando a “Declaração de Helsínquia” da Associação Médica Mundial 
(Helsínquia 1964; Tóquio 1975; Veneza 1983; Hong Kong 1989; Somerset West 1996 e Edimburgo 
2000) 
 
Nome do Estudo: O efeito da infeção por VIH nos usuários de heroína 
Chamo-me Wilza Beatriz Filipe Fumo, sou médica generalista moçambicana que no momento estou a 
fazer Mestrado em Ciências de Saúde na Universidade do Minho que inclui a realização de um projeto 
de tese. 
Gostaria de convidar o Senhor (a) a participar neste projeto de investigação que se intitula: Efeitos do 
cortisol, colesterol, grau de imunodeficiência, ansiedade e depressão na avaliação do Risco Suicidário 
nos Pacientes VIH positivos. 
 
1 – Introdução 
O suicídio é considerado uma causa importante de morte pela Organização Mundial Da Saúde (OMS). 
A sua ocorrência é maior na presença de doenças crónicas, como é o caso da infeção pelo Vírus de 
Imunodeficiência Humana (VIH), em pessoas jovens e usuárias de drogas. 
Estudos têm associado algumas perturbações psiquiátricas, nomeadamente a depressão e ansiedade, 
bem como baixas concentrações de colesterol e altas concentrações de cortisol com um aumento na 
sua frequência. 
Por outro lado, as células T CD4 sofrem alterações durante a infeção pelo VIH, com tendência a 
reduzir as suas concentrações no seu decorrer pelo que são utilizadas para controlar a progressão da 
doença. Contudo, falta perceber se existe alguma relação entre os seus níveis e a tendência 
aumentada para cometer suicídio neste grupo. 
O objetivo do presente estudo é investigar o efeito da infeção por VIH nos usuários de heroína. 
Adicionalmente, procurar associações entre as perturbações psiquiátricas, os níveis do cortisol e o 
risco de suicídio entre as pessoas infetadas pelo VIH, procurando identificar em que fase da infeção 
este risco predomina como forma de desenvolver estratégias ou melhorar as já existentes para 
controlá-lo. 
Para tal, os participantes irão responder a um questionário para apurar dados sociodemográficos bem 
como informação clínica relevante que já tenha sido implicada no aumento do risco suicidário. 
Para rastreio das perturbações neuropsiquiátricas, serão usadas escalas para a medição da 
ansiedade, da depressão e do stresse percebido. 
O risco de suicídio será obtido através do preenchimento de uma escala de ideação suicida.   
Paralelamente iremos colher amostras de saliva para daí medir a concentração do cortisol (que é uma 
hormona usada para quantificar o stress), que serão codificadas e conservadas em condições 
adequadas com fins estritamente de investigação no Instituto de Ciências da Vida e Saúde (ICVS) da 
Universidade do Minho. 
Informação relativa às concentrações das células T CD4 serão extraídas dos processos clínicos dos 
participantes. 
Em nenhuma fase do estudo serão divulgados dados confidenciais do doente. Durante o processo de 
análise não será possível saber a identificação dos doentes envolvidos no estudo.  
No entanto, os dados poderão ser observados por um comité de Ética e podem ser publicados em 
jornais científicos ou em outros lugares sem que a sua identidade seja revelada. 
Este estudo conta com a colaboração da Universidade do Minho, na Escola de Ciências de 
Saúde/ICVS, e contará com a orientação científica da Profᵃ. Doutora Margarida Correia Neves, 
Professora e investigadora no ICVS e do Professor Doutor António Pacheco Palha. 
O estudo teve a aprovação pelo Centro de Respostas Integradas de acordo com a lei vigente. 
A realização dos testes por si só não tem influência direta na sua doença nem acarreta quaisquer 
riscos. No entanto, alguns testes poderão tornar-se “cansativos” pelo que tem todo o direito de 
interrompê-los ou recusar realizá-los. 
 
Você é livre para optar por participar no estudo. Se recusar participar, não perderá quaisquer 
benefícios relativos à orientação da sua doença. Uma vez integrado no estudo pode também a 
qualquer momento abandoná-lo, sem qualquer prejuízo para o seu futuro acompanhamento clínico. 
 
Muito obrigada pela sua atenção! 
 
 
O investigador 
Wilza Fumo 
 
 
 
  
2- Autorização 
Eu, abaixo assinado, (nome completo do participante)_______________________________ 
_________________________________________________________________________, 
Compreendi a explicação que me foi fornecida, por escrito e verbalmente, da investigação que se 
tenciona realizar, para qual é pedida a minha participação. 
Foi-me dada a oportunidade de fazer as perguntas que julguei necessárias, e para todas obtive 
resposta satisfatória. 
Tomei conhecimento de que, de acordo com as recomendações da Declaração de Helsínquia, a 
informação que me foi prestada versou os objetivos, os métodos, os benefícios previstos, os riscos 
potenciais e o eventual desconforto. Além disso, foi-me afirmado que tenho o direito de decidir 
livremente aceitar ou recusar a todo o tempo a minha participação no estudo. Sei que se recusar não 
haverá qualquer prejuízo na assistência que me é prestada. 
Foi-me dado todo o tempo de que necessitei para refletir sobre esta proposta de participação. 
Nestas circunstâncias, decido livremente aceitar participar neste projeto de investigação, tal como me 
foi apresentado pelo investigador (a). 
 
Nome do Participante 
 
Assinatura do Participante 
___________________________________________________________________________
___ 
Data _____/_____/_____ 
Assinatura do Coordenador do estudo 
___________________________________________________________________________
___ 
Data _____/_____/_____ 
Assinatura da pessoa que obteve o consentimento 
__________________________________________________________________ 
Data _____/_____/_____ 
 
 
 
 
 
 
 
  
 
 
 QUESTIONÁRIO – RISCO SUICIDÁRIO E VIH 
 
Número de inquérito: ___________                                          Data:___/_____/_____ 
 
1.Identificação 
1.1.Nome (iniciais) _______                                    1. 2.Número do processo__________ 
1.3. Sexo     0. Masculino          1. Feminino    (_____)      1.4 
Idade_______ 
1.4. Estado Civil   1.Solteiro    2. Casado   3. Divorciado   4. Viúvo (____) 
1.5.Residência 1.Urbano     2. Semiurbano         3. Rural (_____) 
1.6. Nível educacional (anos de estudo)____ _______________ 
1.7. Ocupação     0. Empregado       1. Desempregado        2. Estudante (_____) 
 
2. Hábitos de vida 
2.1. Tabágicos             0. Não_____      1. Sim_____ 
2.1.1. Se SIM, quantificar (U.M.A.)________ 
2.2 Hábitos alcoólicos     0. Não_____    1. Sim______ 
2.2.1 Há quanto tempo não ingere álcool (dias)?_____ 
2.2.1 Se sim, quantificar (g/dia)_____ 
2.3. Uso de drogas endovenosas  0. Não_____       1. Sim _____ 
2.3.1 Tipo de droga   0. Morfina  1. Heroína   2. Cannabis  3. Barbitúricos   4. Outro  (______) 
2.3.2 Há quanto tempo está abstinente (dias)?_____ 
2.3.2 Tratamento actual    0. Metadona     1. Buprenorfina    2. Nenhum    3. Outro  (______) 
2.4. Uso de anticonceptivos orais   0. Não___    1.sim_____ 
 
2.5. Data da última menstruação (D.U.M) ____/_____/_____ 
2.6 Tem filhos?    0. Não___      1. Sim_____        
2.7 Com quem vive? 0. Sozinho       2. Acompanhado  (____) 
 
 
3. Doença psiquiátrica concomitante______________________________________ 
 
4. Tratamento psiquiátrico 0. Não___     1. Sim_____ 
4.1 Grupo farmacológico 
1. Antidepressivos     2. Antipsicóticos   3. Estabilizadores do humor 4. Ansiolíticos  5. Outros  (____) 
 
5. Antecedentes de suicídio_______________________________________________ 
 
6. Tempo desde a última tentativa (meses)___________________________________ 
 
5. História familiar psiquiátrica_____________________________________________ 
 
6. História familiar de tentativa de suicídio___________________________________ 
 
7. Comorbilidades 
1. HTA       2. DM      3. Epilepsia     4. Cancro    5.Perturbação da personalidade     6.Outra  (_____) 
 
7. Duração da confirmação de diagnóstico (meses) ____________________________ 
 
8. Via de transmissão 
1. Sexual  2. Partilha de seringas 3 Desconhece   (______)    
 
9. Orientação sexual 
1. Heterossexual     2. Homossexual     3. Bissexual (_____) 
8. Em TAR               0. Não ____       1.Sim_____ 
 
8.1. Há quanto tempo? (anos)_________ 
8.2. Regime terapêutico __________________________________________________ 
 
9. Dados antropométricos 
10.1 Altura (metros) 
10.2 Peso (quilos) 
10.3 Índice  de massa corporal (IMC) (kg/m²) 
 
10. Exames complementares 
11.1Colesterol (mmol/L)_________ 
11.2Cortisol salivar (µg/dL)________ 
11.3CD4 (número de células/microlitro)__________ 
11.4 Carga viral (cópias/mL)___________ 
11.5 Monócitos (número de células/mm³ de sangue)____________ 
 
 
 
 
 
 
 
 
 
 
 

 
